Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia

Späth, M.; Stratz, T; Neeck, Gunther; Kötter, Ina; Hammel, B; Amberger, CC; Haus, Ulrike; Färber, L; Pongratz, D.; Müller, Wolfgang

doi:10.1080/03009740410005818

Cited by 58 publications

(24 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tropisetron, a 5-hydroxytryptamine type-3 receptor antagonist, and 5-hydroxytryptophan, an intermediate metabolite of L-tryptophan, were more effective than placebo in randomized, controlled trials [34,35]. S-adenosylmethionine, an agent with anti-inflammatory and antidepressant effects, was found to be beneficial in improving pain in one study, but appeared to do no better than placebo in a second study for patients with FM [36].…”

Section: Adjunctive Analgesic Therapiesmentioning

confidence: 99%

Pharmacologic treatment of fibromyalgia

Baker

Barkhuizen

2005

Current Science Inc

View full text Add to dashboard Cite

Fibromyalgia is a syndrome of widespread pain, nonrestorative sleep, disturbed mood, and fatigue. Optimal treatment involves a multidisciplinary approach with a team of health care providers using pharmacologic and nonpharmacologic treatment. Because of the heterogeneity of the illness, management should be individualized for the patient. Pharmacologic treatment should address issues of pain control, sleep disturbance, fatigue, and any underlying coexisting mood disorder. Nonpharmacologic treatment should include patient education, a regular exercise and stretching program, and cognitive behavioral therapy. All of these are essential to improving functional capacity and quality of life. This review provides general guidelines in initiating a successful pharmacologic treatment program for patients with fibromyalgia.

show abstract

Section: Adjunctive Analgesic Therapiesmentioning

confidence: 99%

Pharmacologic treatment of fibromyalgia

Baker

Barkhuizen

2005

Current Science Inc

View full text Add to dashboard Cite

show abstract

“…Eine kleine (n=21), ebenfalls placebokontrollierte, Nachfolgestudie wies tendenziell auf eine stärkere Effektivität bei parenteraler Applikation (5 mg/5 Tage) hin, statistische Signifikanz wurde jedoch für keinen der Erfolgsparameter erreicht [28]. FMS-Patienten mit Depressionen sprechen offensichtlich weniger auf Tropisetron an.…”

Section: Tropisetronunclassified

Fibromyalgiesyndrom

Harten¹

2007

Z. Rheumatol.

View full text Add to dashboard Cite

Fibromyalgia syndrome (FMS) affects 2-10% of the adult population in industrial countries and although it is associated with substantial morbidity and disability, treatment options are unsatisfactory. The rapid growth of trials for FMS in recent years has resulted in new, evidence-based approaches to medical treatment. This review focuses on the randomized, controlled studies of newer pharmacological options for FMS, such as selective serotonin/norepinephrine reuptake inhibitors (duloxetine, milnacipran), inhibitors of voltage-gated calcium channels (pregabalin, gabapentin), dopamine-2/3-receptor agonists (pramipexole, ropirinole), sedative-hypnotic agents (sodium oxybate, modafinil, dronabinol), 5-HT3 antagonists (tropisetron) and others (tramadol, dextromethorphan, olanzapine).

show abstract

“…Die Effektstärke betrug 1,87 (ab 0,8 starke Effekte). Diese Besserungsrate war deutlich höher als in den voran gegangenen Tropisetron-Studien [8,24,25] und dürfte mit der strengen Selektion der behandelten Patienten zusammenhängen [26].…”

Section: Primäre Fibromyalgien Mit Starker Druckempfindlichkeit Der Tunclassified

Ein Modell zur Einteilung des Fibromyalgiesyndroms

Müller

Schneider

Joos

et al. 2007

Schmerz

View full text Add to dashboard Cite

As has been shown by a number of working groups, primary fibromyalgia syndrome does not represent a single clinical entity. It is possible to distinguish between a subgroup with high pain sensitivity and no associated psychiatric condition, a second subgroup characterized by depression and concomitant pain symptoms associated with fibromyalgia syndrome, and a third group with somatoform pain disorder of the fibromyalgia type. Bland inflammatory processes must be considered as the cause in the first group, while depression is the underlying reason for the development of pain in the second group. In the third group, serious previous or still existing psychological problems or also insufficient coping with illness symptoms must be regarded as the reason for pain chronification. Group 1 benefits from a blocking of the 5-HT3 receptors by means of tropisetron, for example. This not only affects pain chronification but also the inflammatory process itself. Group 2 needs antidepressant treatment, whereas the focus should be on psychotherapy is group 3. Groups 1 and 2 will also profit from multimodal physical treatment programs; to a certain extent this applies to group 3 as well. So-called mixed types require a combination of therapeutic measures.

show abstract

Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia

Abstract: 5-HT(3) receptor antagonists provide significant pain relief for a group of FM patients.

Cited by 58 publications

References 17 publications

Pharmacologic treatment of fibromyalgia

Pharmacologic treatment of fibromyalgia

Fibromyalgiesyndrom

Ein Modell zur Einteilung des Fibromyalgiesyndroms

Contact Info

Product

Resources

About